Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak

NEW YORK, April 3 (Bernama-BUSINESS WIRE) -- Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, ethical choices, effectiveness of government responses, and much more. Multiple study waves including a deeper dive into treatments will be conducted over the next several weeks. To view results and countries visit sermo.com.

Key findings; Sermo Real Time Barometer *:

Treatments & Efficacy

· The three most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine
· Hydroxychloroquine usage amongst COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK, and 7% in Japan
· Hydroxychloroquine was overall chosen as the most effective therapy amongst COVID-19 treaters from a list of 15 options. (37% of COVID-19 treaters)
o 75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in the U.S., and 13% in the UK

· The two most common treatment regimens for Hydroxychloroquine were:
o (38%) 400mg twice daily on day one; 400 mg daily for five days
o (26%) 400mg twice daily on day one; 200mg twice daily for four days
· Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
· Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients

Second Wave of Outbreak

· The second global outbreak is anticipated by 83% of global physicians, 90% of U.S. physicians but only 50% of Chinese physicians

Average Testing Time

· On average tests in the U.S. take 4-5 days, and in 10% of cases the wait is more than 7 days
· 14% of U.S. physicians and over 50% in all of Europe and Japan report getting test results in 24 hours; in China 73% of doctors get tests back in 24 hours, while 8% get tests back within the hour

Prioritizing Treatment if Ventilator Shortage

· In all countries except China, the top criteria for deciding who should receive a ventilator first was patients with the highest chance of recovery (47%) followed by those most ill and at highest risk of death (21%), then first responders (15%)
o In China the priorities were reversed as the most ill and highest risk of death received ventilators

· First responders were more important in the U.S.
· France, Japan, and Italy prioritized age
· Brazil and Russia prioritized higher risk patients

Peak Timing & Restrictions

· In the U.S., 63% of physicians recommend restrictions be lifted six or more weeks from now and 66% believe the peak is at least 3-4 weeks away

For the full methodology click here.

“This is a treasure trove of global insights for policy makers. Physicians should have more of a voice in how we deal with this pandemic and be able to quickly share information with one another and the world,” said Peter Kirk, CEO, Sermo. “With censorship of the media and the medical community in some countries, along with biased and poorly designed studies, solutions to the pandemic are being delayed. We invite global physicians to contribute to help inform policy makers, their colleagues, and the public.”

*Results provide physician observations but are not a substitute for official medical guidelines.

Methodology

Results are reported for individual countries with a minimum sample size of 250. Such a sample size provides for point estimates with a +/- 6% precision at a 94% confidence level. Thirty countries included in the study are the United States, Canada, Argentina, Brazil, Mexico, Germany, Italy, the United Kingdom, France, Spain, Belgium, the Netherlands, Sweden, Turkey, Poland, Russia, Finland, Ireland, Switzerland, Austria, Denmark, Norway, Greece, Taiwan, Japan, South Korea, Australia, China, India, and Hong Kong. No incentive was offered to respondents. Full methodology.

About Sermo

Sermo is the largest healthcare data collection company and social platform for physicians, reaching 1,3MM HCPs across 150 countries. The platform enables doctors to anonymously talk real-world medicine, review treatment options via our proprietary Drug Ratings platform, collectively solve patient cases, and participate in medical market research. For more information, visit sermo.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20200402005460/en/

Contact

Media:
Niki Franklin
Racepoint Global on behalf of Sermo
+1 617 624 3264
Sermo@racepointglobal.com

Source : Sermo

--BERNAMA